It's good to see Nina very bullish. Some points worth noting...

It's good to see Nina very bullish.

Some points worth noting when comparing to Chemocentryx:
1) Effectiveness:
The effectiveness of both DMX200 and the Chemocentryx drug CCX140 in phase 2a trials was measured using "reduction of proteinuria"

I understand that DMX200 saw much larger decreases in proteinuria than CCX140 in completed trials.
This taken from a 2019 Taylor Collison report:


https://investors.dimerix.com/FormBuilder/_Resource/_module/NmTFFw2QYECW7FAyONzmbw/docs/Dimerix-20191120-Taylor-Collison-Initiation.pdf

2) Patent protection directly relating to Chemocentryx CCX140

This is an example of how forward-thinking Dimerix was. A few years back significant work was done protecting the IP of DMX200. One particular patent (#9314450) was procured 4 years ago may actually prevent CCX140 from being used in certain (major) jurisdictions.





http://www.ndfresearch.com/uploads/8/1/7/4/81743720/2017_03_27_dimerix_ltd_update_report_from_ndf.pdf